Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States (13% of 2024 revenues), diagnostic products (20% of 2024 revenues), nutritional products (22% of 2024 revenues), and medical devices (45% of 2024 revenues).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 2026-08-31 09:57:25 | 110.41 | -2.01 | -1.79 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT | 0000001800 | ABBOTT LABORATORIES | US0028241000 | 549300JBDVIIMW4FW262 | 360698440 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | IL | 100 ABBOTT PARK ROAD | ABBOTT PARK | IL | 60064-3500 | UNITED STATES | US | 2246676100 | 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-3500 | 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-3500 | — | Health care | 1888 | Robert B. Ford | 115,000 | http://abbott.com | 232,169,255,381 | 1,998,233,756 | 1,741,812,429 | Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States (13% of 2024 revenues), diagnostic products (20% of 2024 revenues), nutritional products (22% of 2024 revenues), and medical devices (45% of 2024 revenues). | 2026-08-27 18:07:56 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 232,169,255,381 | 55,095,271,422 | 31.1143 | 1,737,682,887 | 3,359,476 | 0.1937 |
| 2024 | 177,073,983,959 | -8,097,350,351 | -4.3729 | 1,734,323,411 | -860,878 | -0.0496 |
| 2023 | 185,171,334,310 | -933,711,880 | -0.5017 | 1,735,184,289 | -2,761,944 | -0.1589 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Lisa D. Earnhardt | Group President, Executive Vice President | 2025 | 924,231 | — | 2,543,989 | 1,283,400 | 178,953 | 8,069,724 |
| Daniel G. Salvadori | Group President, Executive Vice President | 2025 | 924,231 | — | 2,238,786 | 388,200 | 212,501 | 6,534,285 |
| Robert B. Ford | Chief Executive Officer, Chairman Of The Board | 2025 | 1,500,000 | — | 8,787,378 | 1,968,750 | 959,798 | 24,198,660 |
| Philip P. Boudreau | Chief Financial Officer, Executive Vice President | 2025 | 974,231 | — | 3,045,935 | 1,055,400 | 74,418 | 9,090,636 |
| Christopher J. Scoggins | Executive Vice President | 2025 | 859,502 | — | 1,662,503 | 1,095,300 | 108,443 | 6,601,667 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 115,000 |
| 2024 | 114,000 |
| 2023 | 114,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 44,328,000,000 | 41,950,000,000 | 40,109,000,000 |
| Cost Of Revenue | 19,319,000,000 | 18,706,000,000 | 17,975,000,000 |
| Gross Profit | 25,009,000,000 | 23,244,000,000 | 22,134,000,000 |
| Research And Development Expenses | 2,942,000,000 | 2,844,000,000 | 2,741,000,000 |
| General And Administrative Expenses | 12,332,000,000 | 11,697,000,000 | 10,949,000,000 |
| Operating Expenses | 36,275,000,000 | 35,125,000,000 | 33,631,000,000 |
| Operating Income | 8,053,000,000 | 6,825,000,000 | 6,478,000,000 |
| Net Income | 6,524,000,000 | 13,402,000,000 | 5,723,000,000 |
| Earnings Per Share Basic | 3.73 | 7.67 | 3.28 |
| Earnings Per Share Diluted | 3.72 | 7.64 | 3.26 |
| Weighted Average Shares Outstanding Basic | 1,741,000,000 | 1,740,000,000 | 1,740,000,000 |
| Weighted Average Shares Outstanding Diluted | 1,748,000,000 | 1,748,000,000 | 1,749,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 8,522,000,000 | 7,616,000,000 | 6,896,000,000 |
| Marketable Securities Current | 417,000,000 | 351,000,000 | 383,000,000 |
| Accounts Receivable | 7,929,000,000 | 6,925,000,000 | 6,565,000,000 |
| Inventories | 6,488,000,000 | 6,194,000,000 | 6,570,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 25,996,000,000 | 23,656,000,000 | 22,670,000,000 |
| Marketable Securities Non Current | 918,000,000 | 886,000,000 | 799,000,000 |
| Property Plant And Equipment | 11,816,000,000 | 10,658,000,000 | 10,154,000,000 |
| Other Assets Non Current | 1,200,000,000 | 784,000,000 | 787,000,000 |
| Total Assets Non Current | 22,200,000,000 | 18,500,000,000 | 16,200,000,000 |
| Total Assets | 86,713,000,000 | 81,414,000,000 | 73,214,000,000 |
| Accounts Payable | 4,240,000,000 | 4,195,000,000 | 4,295,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 3,033,000,000 | 1,500,000,000 | 1,080,000,000 |
| Other Liabilities Current | 569,000,000 | 594,000,000 | 492,000,000 |
| Total Liabilities Current | 16,496,000,000 | 14,157,000,000 | 13,841,000,000 |
| Long Term Debt | 12,929,000,000 | 14,125,000,000 | 14,679,000,000 |
| Other Liabilities Non Current | 2,538,000,000 | 3,443,000,000 | 3,466,000,000 |
| Total Liabilities Non Current | 18,087,000,000 | 19,593,000,000 | 20,770,000,000 |
| Total Liabilities | 34,583,000,000 | 33,750,000,000 | 34,611,000,000 |
| Common Stock | 25,527,000,000 | 25,153,000,000 | 24,869,000,000 |
| Retained Earnings | 49,781,000,000 | 47,261,000,000 | 37,554,000,000 |
| Accumulated Other Comprehensive Income | -6,001,000,000 | -7,906,000,000 | -7,839,000,000 |
| Total Shareholders Equity | 52,130,000,000 | 47,664,000,000 | 38,603,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,434,000,000 | 1,340,000,000 | 1,277,000,000 |
| Share Based Compensation Expense | 664,000,000 | 673,000,000 | 644,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 652,000,000 | 691,000,000 | 356,000,000 |
| Change In Inventories | -195,000,000 | 58,000,000 | 232,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 1,295,000,000 | 796,000,000 | 542,000,000 |
| Change In Accounts Payable | 954,000,000 | 356,000,000 | -760,000,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 9,566,000,000 | 8,558,000,000 | 7,261,000,000 |
| Purchases Of Marketable Securities | 167,000,000 | 169,000,000 | 159,000,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 2,171,000,000 | 2,207,000,000 | 2,202,000,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | -18,000,000 | -9,000,000 | -22,000,000 |
| Cash From Investing Activities | -2,422,000,000 | -2,338,000,000 | -3,133,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 893,000,000 | 1,295,000,000 | 1,227,000,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -82,000,000 | — | — |
| Cash From Financing Activities | -6,309,000,000 | -5,404,000,000 | -7,091,000,000 |
| Change In Cash | 906,000,000 | 720,000,000 | -2,986,000,000 |
| Cash At End Of Period | 8,522,000,000 | 7,616,000,000 | 6,896,000,000 |
| Income Taxes Paid | 1,933,000,000 | 1,723,000,000 | 1,475,000,000 |
| Interest Paid | 545,000,000 | 604,000,000 | 662,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 3.73 | 7.67 | 3.28 |
| Price To Earnings Ratio | 33.5898 | 14.7471 | 33.5579 |
| Earnings Growth Rate | -51.369 | 133.8415 | -16.7513 |
| Price Earnings To Growth Ratio | -0.6539 | 0.1102 | -2.0033 |
| Book Value Per Share | 29.9426 | 27.3931 | 22.1856 |
| Price To Book Ratio | 4.1843 | 4.1291 | 4.9613 |
| Ebitda | 10,384,000,000 | 17,024,000,000 | 9,112,000,000 |
| Enterprise Value | 225,569,890,000 | 204,820,400,000 | 200,384,800,000 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.3062 | 0.3278 | 0.4082 |
| Capital Expenditures | 2,592,000,000 | 1,844,000,000 | 2,269,000,000 |
| Free Cash Flow | 6,974,000,000 | 6,714,000,000 | 4,992,000,000 |
| Return On Equity | 0.1251 | 0.2812 | 0.1483 |
| One Year Beta | 0.2285 | 0.1988 | 0.5808 |
| Three Year Beta | 0.3066 | 0.6741 | 0.727 |
| Five Year Beta | 0.5417 | 0.762 | 0.8225 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Ford Robert B | Director, CHAIRMAN AND CEO | 2026-08-25 | 246,963 | A | 705,293 |
| Ford Robert B | Director, CHAIRMAN AND CEO | 2026-08-25 | 218,535 | D | 486,758 |
| Ford Robert B | Director, CHAIRMAN AND CEO | 2026-08-25 | 180,297 | D | 306,461 |
| Ford Robert B | Director, CHAIRMAN AND CEO | 2026-08-25 | 151,869 | D | 0 |
| Ford Robert B | Director, CHAIRMAN AND CEO | 2026-08-25 | 151,869 | A | 458,330 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senator | 2026-07-21 | Sale (Full) | 2026-03-27 | Self | $15,001 - $50,000 |
| Shelley M Capito | Senator | 2025-03-06 | Sale (Partial) | 2025-02-24 | Spouse | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-01-31 | Sale (Full) | 2025-01-08 | Joint | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2024-12-31 | Sale (Partial) | 2024-12-11 | Joint | $15,001 - $50,000 |
| Thomas R Carper | Senator | 2024-02-02 | Sale (Partial) | 2024-01-17 | Spouse | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Richard W. Allen | 2026-08-18 | GA12 | Sale | 2026-07-14 | Spouse | $15,001 - $50,000 |
| Richard Dean Dr McCormick | 2026-08-14 | GA06 | Sale | 2026-07-30 | — | $1,001 - $15,000 |
| Mike Kelly | 2026-08-12 | PA16 | Sale | 2026-07-17 | Spouse | $1,001 - $15,000 |
| Rick Larsen | 2026-07-12 | WA02 | Sale | 2026-07-08 | — | $1,001 - $15,000 |
| Richard Dean Dr McCormick | 2026-07-09 | GA06 | Purchase | 2026-06-12 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Cornerstone Financial Management LLC | 2026-06-30 | 20,689 | 228 | 90.7412 |
| Corient Private Wealth LLC | 2026-06-30 | 165,009,873 | 1,818,488 | 90.7401 |
| VELA Investment Management, LLC | 2026-06-30 | 4,980,900 | 54,892 | 90.74 |
| TUCKER ASSET MANAGEMENT LLC | 2026-06-30 | 314,604 | 3,467 | 90.7424 |
| HORAN Wealth, LLC | 2026-06-30 | 3,511,492 | 38,698 | 90.7409 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| PIMCO Equity Series | 2026-06-30 | PIMCO RAFI ESG U.S. ETF | RAFE | 15,100 | 1,370,174 | 0.8538 |
| DIAMOND HILL FUNDS | 2026-06-30 | Diamond Hill Select Fund Class Y | DHTYX | 376,825 | 34,193,100.5 | 6.2901 |
| DIAMOND HILL FUNDS | 2026-06-30 | Diamond Hill Select Fund Class I | DHLTX | 376,825 | 34,193,100.5 | 6.2901 |
| DIAMOND HILL FUNDS | 2026-06-30 | Diamond Hill Select Fund Investor | DHTAX | 376,825 | 34,193,100.5 | 6.2901 |
| DIAMOND HILL FUNDS | 2026-06-30 | Diamond Hill Long-Short Fund Class Y | DIAYX | 673,067 | 61,074,099.58 | 2.8932 |